Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

AGM and Interim Management Statement

8 Nov 2012 07:00

RNS Number : 6077Q
Genus PLC
08 November 2012
Β 

ο»Ώ

For immediate release

8 November 2012

Β 

Β 

Genus plc

('Genus' or 'the Company')

Annual General Meeting ('AGM') and Interim Management Statement

Β 

At the AGM of Genus to be held at 11.00am today, the following interim management statement will be made for the trading period from 1 July to 31 October 2012.

Β 

Current Trading

Following last year's record results, revenues for the four months to 31 October 2012 were slightly ahead of the strong performance achieved in the same period last year. Operating profits were lower than the same period last year driven by higher feed costs in our genetic nucleus farms and by delayed sales in Genus ABS caused by adverse weather conditions in Latin America.

Β 

The overall results have benefited from solid performances in Genus PIC and Genus Asia. In addition the strength of the Genus business model has limited the financial effect on Genus of the higher feed costs that are affecting many of our customers.

Β 

Genus PIC, comprising the porcine operations in North America, Latin America and Europe, achieved continued volume growth across all three regions. Operating profits were at a similar level to last year despite higher feed costs in our nucleus farm operations and planned increased investment in product development. Performance has benefited from continued growth in the CBV Plus and CBV Max programmes in North America and volume growth in Latin America. Europe has performed ahead of last year reflecting the start of restructuring benefits and the strengthening European porcine market.

Β 

Genus ABS, comprising the dairy and AI beef businesses in North America, Latin America and Europe, had a slow start to the year. Volumes were lower in Latin America where adverse weather conditions in Argentina and Brazil have caused a delay in semen sales. We expect these sales to be recovered as the year progresses. Performance in North America and Europe was slightly ahead of last year.

Β 

Genus Asia has had a good start to the year. Revenues and profits were in line with the strong performance achieved in the same period last year.

Β 

As expected finance costs were higher than last year, reflecting the previously indicated increase in pension interest costs following the additional pension provision made at 30 June 2012.

Β 

Financial Position

Net debt at the end of October 2012 was at a similar level to end June 2012 and well below the same time last year.

Β 

Strategy

We have made a good start in implementing our strategy to accelerate the rate of profit growth from 2014 onwards.

Β 

Following the implementation of a new market-place oriented organisation structure in July 2012, we are establishing global technical services, global marketing and a global supply chain for each of our porcine and dairy/AI beef businesses. This is already starting to create opportunities to enhance customer service which is a key element of our overall growth strategy.

Β 

In line with our strategy, we have appointed Saskia Korink Romani to the new position of Chief Marketing Officer. Saskia, who joins in January 2013, brings significant international business and marketing experience having worked for 10 years at Cargill, most recently as Vice President of Marketing, Animal Nutrition Division.

Β 

In Asia, key personnel appointments have been made as part of our plans to ensure we have the right resources in place to meet our growth aspirations.

Β 

In China, the initial stocking of the Besun porcine joint venture farm has been completed as planned and discussions with other potential joint venture partners are progressing.

Β 

Outlook

We expect to see a gradual improvement in performance as the year progresses particularly after the slow start in our Genus ABS business. We believe Genus remains on course to achieve another year of growth.

Β 

With the investments being made in the current year, particularly in emerging markets such as China and in core competencies such as marketing, technical services and product development, the Group is well placed to take advantage of the long-term opportunities available in the global animal genetics market.

Β 

Β 

For further information please contact:-

Β 

Genus plc: Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

Β 

Β 

Buchanan: Tel: 0207 466 5000

Charles Ryland

Β 

This announcement is available on the Genus website, www.genusplc.com

Β 

Β 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across all livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Β 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Genus' customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chain.

Β 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

Β 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCUBUURURAARUA
Date   Source Headline
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.